Team

A team that has generated over $5B in shareholder value across prior ventures.

Experienced drug development team led by CEO Laura Hix Glickman, PhD, a serial biotech founder with a clear scientific and strategic vision, and a proven track record to deliver accelerated results on a highly capital efficient budget.

Leadership

Leading Adjuvia

  • Laura Hix Glickman, PhD

    CO-FOUNDER & CEO

    Serial entrepreneur and inventor with over $2.5B in financings, licensing deals, acquisitions and IPOs. Co-inventor on Adjuvia intellectual property.

  • Tim Wilson

    CO-FOUNDER & CHAIRMAN

    Company founder with decades of experience building and scaling private and public companies, as an operator, board member and venture capitalist.

  • Kelly Bryant

    CHIEF OPERATING OFFICER

    Operations and business leader across healthcare, biotech and medtech, guiding our programs from IND through clinical development.

  • Gurdyal Kalsi, MD, MFPM

    CHIEF MEDICAL OFFICER

    Clinical, regulatory and medical lead on multiple study protocols and development plans, with a focus on genetic and rare diseases.

Advisors

Drug development, regulatory and legal

  • Sara Semnani

    Lead Partner & Corporate Counsel, Cooley LLP

  • Richard Gearhart, Esq.

    Former Head of U.S. Patent and Trademark Groups, Novartis; former General Patent Counsel, Ciba Vision

  • Geno Germano

    Former Group President, Pfizer Global Innovative Pharma; executive roles at Intrexon, Wyeth, J&J, Elucida Oncology, Sage Therapeutics

  • Phil Crowley, Esq.

    Corporate Counsel, Life Sciences, Johnson & Johnson (R&D, M&A, finance, commercial, FDA regulation)

  • Frank Sasinowski, M.S., M.P.H., J.D.

    Former Deputy Director, FDA; Director, Hyman, Phelps & McNamara; advisor on 150+ FDA approvals

Advisors

Scientific and clinical advisors

  • Dr. Gregory M. Enns, M.D.

    Professor of Pediatrics in the Division of Medical Genetics, Stanford University; Director of Biochemical Genetics Program; Mitochondrial Genetic Diseases; Clinical Biochemical Genetics; mRNA and Gene Therapies

  • Aaron Esser-Kahn, PhD

    Professor of Molecular Engineering, Pritzker School of Molecular Engineering, University of Chicago — immunoengineering, NF-κB inhibitors, inflammatory responses

  • Peter Havel, PhD, DVM

    Professor of Nutrition and Molecular Biosciences, UC Davis School of Veterinary Medicine — Alzheimer’s disease and metabolic dysfunction